Randomized, double-blind, placebo-controlled, multi-center, proof of concept study to evaluate the effect of sildenafil citrate (Revatio) 20 mg TID on hemodynamics in patients with Portal- Pulmonary Arterial Hypertension (PPAH) Short title: Revatio Portal

随机、双盲、安慰剂对照、多中心、概念验证研究，旨在评估枸橼酸西地那非 (Revatio) 20 mg TID 对门静脉肺动脉高压 (PPAH) 患者血流动力学的影响 简短标题：Revatio Portal

• 批准号: 255364
• 负责人: Granton John T
• 金额: $ 13.72万
• 依托单位: University Health Network (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2012
• 资助国家: 加拿大
• 起止时间: 2012-03-01 至 2015-03-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=255364&lang=en
• 关键词: Portal Hypertension; Pulmonary Hypertension; Randomized Controlled Trial; Sildenafil

Patients with liver disease can develop a condition known as pulmonary hypertension. In pulmonary hypertension there is a progressive narrowing of the small blood vessels as they travel through the lung. This narrowing puts stress on the right side of the

肝病患者可能会出现肺动脉高压。在肺动脉高压中，当小血管穿过肺时，小血管逐渐变窄。这种狭窄将应力放在右侧，